Investment House LLC Makes New $574,000 Investment in Molina Healthcare, Inc $MOH

Investment House LLC purchased a new stake in Molina Healthcare, Inc (NYSE:MOH) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 3,000 shares of the company’s stock, valued at approximately $574,000.

Several other large investors have also modified their holdings of MOH. Baird Financial Group Inc. purchased a new stake in Molina Healthcare in the first quarter valued at approximately $210,000. NewEdge Advisors LLC raised its stake in Molina Healthcare by 33.4% during the first quarter. NewEdge Advisors LLC now owns 1,106 shares of the company’s stock worth $364,000 after purchasing an additional 277 shares during the period. Jones Financial Companies Lllp boosted its holdings in shares of Molina Healthcare by 713.3% in the 1st quarter. Jones Financial Companies Lllp now owns 1,651 shares of the company’s stock valued at $544,000 after purchasing an additional 1,448 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of Molina Healthcare by 19.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 249,466 shares of the company’s stock valued at $82,172,000 after purchasing an additional 40,531 shares during the last quarter. Finally, Woodline Partners LP purchased a new stake in shares of Molina Healthcare during the 1st quarter valued at $1,541,000. 98.50% of the stock is currently owned by hedge funds and other institutional investors.

Molina Healthcare Stock Up 1.7%

NYSE MOH opened at $202.05 on Monday. The company has a quick ratio of 1.68, a current ratio of 1.68 and a debt-to-equity ratio of 0.92. Molina Healthcare, Inc has a fifty-two week low of $133.40 and a fifty-two week high of $359.97. The business has a 50 day moving average price of $166.11 and a two-hundred day moving average price of $172.44. The stock has a market cap of $10.95 billion, a PE ratio of 12.51 and a beta of 0.49.

Wall Street Analysts Forecast Growth

MOH has been the topic of several research reports. Truist Financial set a $175.00 target price on Molina Healthcare in a research report on Friday, October 24th. Wells Fargo & Company boosted their price target on Molina Healthcare from $165.00 to $208.00 and gave the company an “overweight” rating in a research report on Wednesday, January 7th. Barclays upped their price target on Molina Healthcare from $144.00 to $164.00 and gave the stock an “underweight” rating in a research note on Monday, January 5th. Deutsche Bank Aktiengesellschaft set a $165.00 price objective on Molina Healthcare in a research note on Friday, October 24th. Finally, Jefferies Financial Group set a $160.00 target price on Molina Healthcare in a report on Tuesday, December 16th. Three analysts have rated the stock with a Buy rating, ten have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, Molina Healthcare currently has a consensus rating of “Hold” and a consensus price target of $193.47.

Insiders Place Their Bets

In related news, Director Richard M. Schapiro sold 357 shares of the firm’s stock in a transaction on Monday, November 24th. The shares were sold at an average price of $143.02, for a total transaction of $51,058.14. Following the completion of the sale, the director directly owned 11,352 shares of the company’s stock, valued at approximately $1,623,563.04. This trade represents a 3.05% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 1.26% of the company’s stock.

Molina Healthcare Profile

Molina Healthcare, Inc is a managed care company specializing in government-sponsored health insurance programs. The company offers Medicaid managed care plans, Medicare Advantage and prescription drug plans, and individual Marketplace plans under the Affordable Care Act. Through an integrated care model, Molina emphasizes preventive and primary care services, care coordination, and disease management to improve health outcomes for its members.

The company traces its roots to the early 1980s, when Dr.